- Disease
- Tuesday, 23 Jun 2020
Agenus Cell Therapy and Checkpoint Antibody Combinations Show Curative Preclinical Efficacy at AACR 2020
Agenus Inc., an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, announced that it will make a scientific presentation today on optimal anti-cancer combinations with Fc enhanced anti-CTLA-4, AGEN1181, at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting.
"AGEN1181 is an Fc-engineered anti-CTLA-4 that has shown exciting clinical activity in an early phase 1 clinical trial, which was recently presented at ASCO," said Dr. Antoine Tanne, Lead Scientist, Agenus Immune Biology Team. "Today, at AACR, we report that combinations with AGEN1181 demonstrate curative responses in preclinical models resistant to anti-PD-1. These data illustrate the potential of combining allogeneic cell therapies with checkpoint antibodies, such as AGEN1181, to deliver curative benefit in difficult to treat settings."
Related Industry Updates
Majority of the U.S. firms in China see revenue hit from coronavirus: AmCham survey
Feb 07, 2020
South African Rand falls as virus death toll knocks risk appetite
Feb 13, 2020
South Africa should consider zero-based budgeting, finance minister says
Jun 12, 2020
Taiho Oncology Announces Presentation of Data for Futibatinib in Advanced Intrahepatic Cholangiocarcinoma at 2020 ASCO Meeting
Jun 01, 2020
Trump wants America to get back to Business by Easter?
Mar 26, 2020
Reinsurance: A financial Backstop for Businesses During this Pandemic?
Mar 31, 2020
South Koreans petition for Chinese to be Banned entering the country amid virus outbreak
Jan 28, 2020
Follow us on
